

# PANDEMIC PREVENTION, PREPAREDNESS AND RESPONSE APPROACH

BOARD MEETING

**Derrick Sim**

6-7 December 2023, Accra, Ghana



# The Pandemic Preparedness, Prevention and Response (PPPR) approach brings together Gavi's historic contribution to PPPR and its evolution as part of Gavi 5.1

- **PPPR is core to the Alliance's mission** and an integral part of its four strategic goals
- **Gavi's PPPR role evolved in response to the COVID-19 pandemic**, resulting in the Gavi 5.1 strategy and summarised in the proposed PPPR approach
- With climate change and other factors increasing risk of outbreaks and pandemics, **Gavi proposes a set of investments for Gavi 5.1**, learning from COVAX and other recent outbreaks
- **Several global and regional level efforts are underway** to strengthen and shape the future global health and PPPR architecture
- **The aim is to integrate into any future medical counter-measures network**
- **The work would be driven by an expanded coalition of vaccine partners** including, and building on, the group that came together to fight COVID-19
- The nature and level of ambition for PPPR will be considered through the **Gavi 6.0 strategy process**

# The vision of Gavi's PPPR approach is for countries to be ready, with access to vaccines, and supported through a coalition

## PPPR Approach: Ambition for Pandemic Readiness



Enable countries to prevent and respond to outbreaks and foster development of **resilient, flexible health systems** that can quickly pivot to rollout outbreak vaccines, supported by surge funding and technical assistance, with **minimal disruption to routine services**

Incentivise the rapid development and **regionally-diverse manufacture** of outbreak ready **vaccines that are accessible, available, appropriate, and affordable** for lower-income countries

Coalition of **global, regional, and national vaccine partners**, including Civil Society Organisations (CSOs), that are financed, equipped with the **right capabilities and capacities**, and are prepared with a clear plan to respond on Day Zero – having learned the lessons from COVID-19 and other outbreaks

The Board paper sets out an **approach and Theory of Change for Gavi's contribution to PPPR**

# Four immediate investments are proposed for Gavi 5.1

## Further investments may be considered for Gavi 6.0



***Proposals that could be financed through the Pandemic Vaccine Pool (PVP) – aligned with the Theory of Change - based on urgent needs, learnings from COVID-19, and Gavi Alliance expertise and model:***

**A**

**Extraordinary support for recovery and big catch up**

*Ref. Doc 04*

**B**

**Finance African Vaccine Manufacturing Accelerator**

*Ref. Doc 10b*

**C**

**Invest in capabilities to ensure a strong vaccine coalition within the global architecture for PPPR**

**D**

**Accelerate access to at-risk funds through the First Response Fund for the Day Zero Financing Facility**

# PPPR proposals

## Summary

## Expected Outcomes



### Coalition of vaccine partners

**Challenge:** Gaps in strategic partner coordination in the PPPR ecosystem limit equitable and timely access to and delivery of vaccines for low- and middle-income countries (LMICs)

**Proposed Solution:** A coalition of vaccine partners for PPPR, convened during the interpandemic period, that is resourced and equipped to respond, leveraging immunisation investments

**Proposed Investment:** US\$ 22 million

- Increased transparency and coordination
- Coalition of vaccine partners work through existing mechanisms and partnerships and collectively define priorities
- Cross-partner PPPR Playbook for Operational Capabilities for efficient decision-making and response
- Continuous learning through a PPPR global repository of collective experience for knowledge sharing, capability building



### First Response Fund for the Day Zero Financing Facility for Pandemics

**Challenge:** Delayed access to financing in a pandemic can contribute to inequitable vaccine response

**Proposed Solution:** Fund critical activities via a First Response Fund that can be deployed from Day Zero of the next pandemic ahead of other donor liquidity and innovative financing tools

**Proposed Investment:** Up to US\$ 500 million

- Rapid and equitable end-to end vaccine response for low-income countries
- Gavi able to rapidly fund key activities including vaccine procurement, early delivery and demand support, and routine immunisation (RI) protection at the start of a pandemic

# The First Response Fund will meet the need for faster response in the next pandemic as part of Gavi's Day Zero Financing Facility (DZF)

Estimated \$2bn+ required during the first 100 days of a pandemic\*

Gavi's Day Zero Financing Facility (DZF) for Pandemics seeks to meet early funding needs

Vaccine procurement



Secure enough doses to **vaccinate most healthcare workers (HCWs) and vulnerable populations** in Gavi countries

Early demand & delivery support




**Accelerate delivery of vaccines and reduce risk of wastage** by preparing countries and covering delivery costs (training, cold chain equip., TA)

RI protection



**Enhance protection of HCWs with PPE**

- Suite of financing instruments to boost headroom and liquidity from the moment of a Gavi approved response and ahead of cash receipts from donors
- Objective is to ensure more rapid and equitable vaccine access
- First Response Fund will provide immediate financial headroom & liquidity
- Other surge instruments (IFFIm CFM, EIB, DFC) provide access to liquidity from day 50+



\*Assumptions: 15% of total population for Gavi 54 (without India), 1 dose of vaccine at \$5/dose, and all money put into vaccine procurement contracts yields doses. This scenario would cover HCWs (2-5% of pop) but may not cover all front-line workers and vulnerable populations (which may be 10-20% of population). Calculations also assume a cost/dose for delivery, cost for procurement, and surge workforce costs (TA) similar to those needed for C19 response. Average delivery cost per dose: [https://www.who.int/docs/default-source/coronaviruse/act-accelerator/covax/costs-of-covid-19-vaccine-delivery-in-92amc\\_08.02.21.pdf](https://www.who.int/docs/default-source/coronaviruse/act-accelerator/covax/costs-of-covid-19-vaccine-delivery-in-92amc_08.02.21.pdf).

# First Response Fund: key features

Feature	Description
Objective	<ul style="list-style-type: none"> <li>• Enable Gavi to secure more equitable vaccine access by providing access to the headroom and liquidity needed to address funding needs ahead of other sources of liquidity.</li> </ul>
Size	<ul style="list-style-type: none"> <li>• Up to US\$ 500 million</li> </ul>
Duration	<ul style="list-style-type: none"> <li>• 7 years to Dec 31, 2030 (to coincide with Gavi 6.0 strategic period), with Board consent required to roll over funding for a subsequent 5-year period</li> </ul>
Governance	<ul style="list-style-type: none"> <li>• Decision to trigger deployment of funds will be subject to standard Gavi governance processes, under a Board approved programme.</li> </ul>
Treasury	<ul style="list-style-type: none"> <li>• Treasury policy and management to be finalised in H1 2024</li> </ul>
Interest income	<ul style="list-style-type: none"> <li>• To be rolled up and added to the First Response Fund.</li> </ul>
Use of funds (examples)	<ul style="list-style-type: none"> <li>• Procurement of medical countermeasures, including entering into vaccine purchase agreements;</li> <li>• Early vaccine demand generation and delivery;</li> <li>• Protection of routine immunisation;</li> <li>• Manufacture of promising vaccines;</li> <li>• Early R&amp;D and synergies with other global health organisations (as was done during C19 with CEPI);</li> <li>• Risk mitigation (e.g. to support surge manufacturing).</li> </ul>
Risks	<ul style="list-style-type: none"> <li>• Not considered to present any material risk to Gavi.</li> <li>• Inaction considered to put at risk Gavi's ability to stage an early response.</li> </ul>

# Recommendation (1/3)

The Gavi Alliance Programme and Policy Committee **recommends** to the Gavi Alliance Board that it:

- a) **Approve** up to US\$ 22 million to support a coalition of vaccine partners outlined in Annex A to Doc 10a as amended by discussions at the Programme and Policy Committee (PPC) to be committed during the Gavi 5.1 strategic period, in line with Gavi's approach to pandemic prevention, preparedness and response (PPPR);
- b) **Note** that the investment would be to vaccine partners, coordinating through existing mechanisms, ensuring that the scope of activities covers critical linkages across outbreaks, epidemics, and pandemics, and resilient routine immunisation programmes and continues to align with the Intergovernmental Negotiating Body (INB) and medical countermeasures (MCM) network deliberations;
- c) **Note** the PPC's guidance on the programmatic aspects of the investment proposals outlined in Annex A to Doc 10a for the Day Zero Financing Facility for Pandemics for which an estimated amount of up to US\$ 500 million could be allocated, noting that the Gavi Audit and Finance Committee would recommend the Day Zero Financing Facility for Pandemics to the Board for approval;
- d) **Note** that this approval and any additional approvals are contingent on available funding from the COVAX Advance Market Commitment (AMC) Pandemic Vaccine Pool (PVP) as confirmed by the Gavi Audit and Finance Committee;



## Recommendation (2/3)

- e) **Note** that any additional approvals required in the further development of these proposals will be brought back to the Board through the relevant Board committees as per standard Gavi governance process and in line with Gavi policy;
- f) **Note** that the investment proposals were developed with full consideration of enhanced collaboration with other pandemic recovery and PPPR initiatives and considered by the COVAX AMC Investors Group, as requested by the Board in June 2023, and were supported as options for the use of COVAX AMC PVP funds; and
- g) **Note** that the PPPR approach will be further refined for Gavi 6.0, and associated investments considered as part of Gavi 6.0 strategy development, including but not limited to investments presented to the AMC Investors Group that did not receive funding.

## Recommendation (3/3)

The Gavi Alliance Audit and Finance Committee **recommends** to the Gavi Alliance Board that it:

- a) **Approved** the financing of a First Response Fund of up to US\$ 500 million, under Gavi's Day Zero Financing Facility, contingent on the available funding from the COVAX AMC Pandemic Vaccine Pool (PVP);
- b) **Noted** that any additional approvals required to release these funds will be brought back to the Board through the relevant Board Committees as per standard Gavi governance process and in line with Gavi policy;
- c) **Noted** that the financing for the First Response Fund will be held in a ringfenced account with its own reporting requirements; and
- d) **Noted** the importance of establishing appropriate treasury management policies as soon as possible.

# Thank you